Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Cleveland Clinic Abu Dhabi, part of the M42 group, has achieved a historic milestone in global healthcare. In collaboration ...

A 61-year-old patient, initially presenting with urinary complaints, has undergone Stereotactic Body Radiation Therapy (SBRT) for prostate cancer at KMC Hospital Attavar Oncology Centre (KMCHAOC) in ...

It should also include any clinical trials to consider. People with mCRPC, or any advanced prostate cancer, may experience urinary problems, bone pain, fatigue, and weight loss — or possibly no ...

A newly expanded prostate cancer drug could bring new hope to patients with a ... Novartis said it plans to investigate the ...

A person with a prostate can achieve an orgasm using a number of different techniques. These may include using a strap-on, prostate milking, and trying out different positions. The prostate is a ...

No. The palace has only confirmed the King does not have prostate cancer, and has not revealed any further details. In a statement, it said: ‘No further details are being shared at this stage ...

In many cases, particularly with advanced prostate tumors, surgeons will err on the side of caution and forego nerve sparing to make sure all cancer is removed, researchers said. That’s why they ...

“It’s gratifying to see a collaborative effort result in a breakthrough that has the potential to make a difference for so many patients with advanced prostate cancer.” Before receiving the therapy, ...

2 In a press release from the time, Jeff Legos, then executive vice president, global head of oncology development at Novartis said: “These promising results from PSMAfore could change the treatment ...

In many cases, however, these advanced therapies ultimately fail, highlighting the need for new approaches to restore sensitivity in castrate-resistant prostate cancer and improve treatment outcomes.